Bonavis Injection (Ibandronate Sodium Monohydrate)

Adult administration

A dose of 3mg is administered intravenously every 3 months over 15 - 30 seconds. Patients are advised to take calcium and vitamin D as supplements. If a scheduled dose is missed, administer it as soon as possible and continue the regular dosing schedule at 3-month intervals.

This medication must only be administered via intravenous injection, and extreme caution must be taken if improperly administered near arteries or veins to avoid tissue damage. This medication should not be used in patients with a known allergy to it or its ingredients, or in patients with untreated hypocalcemia. Possible side effects during treatment include gastritis, diarrhea, abdominal pain, dyspepsia, nausea, constipation, etc., many of which are mild to moderate and often do not require discontinuation of treatment. Muscle pain, joint pain, headaches, rashes, fatigue, flu-like symptoms have also been reported, and flu-like symptoms may particularly occur during the initial phase of injection. Rarely, long-term use of this medication may result in osteonecrosis of the jaw; hence, it is important to conduct dental screening prior to administration and to avoid excessive dental treatment during therapy. If there is ear pain or discharge, the possibility of osteonecrosis of the external auditory canal should be considered. This medication may cause bone, joint, and muscle pain, and if pain is severe after administration, it is essential to consult with healthcare professionals. Atypical fractures may occur in the femur and other bones, so prompt evaluation should occur if there is pain in the thigh or groin. Pregnant or nursing women are advised not to use this medication due to lack of confirmed safety. This medication may affect kidney function, thus regular check-ups are necessary for patients with renal disease or those taking medications affecting the kidneys. In case of overdose, hypocalcemia, hypophosphatemia, etc., may occur, requiring rapid treatment and monitoring; dialysis may not be effective. This medication should not be mixed with a calcium-containing solution and must only be given as an intravenous injection. Used injection needles and syringes should not be reused and should be disposed of safely.

Serious side effects

Hives, angioedema, facial swelling/edema, anaphylactic reactions/shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, bullous dermatitis, acute renal failure, multiple organ failure, death, fractures, osteonecrosis of the jaw, osteonecrosis of the external auditory canal, hypersensitivity reactions, vascular anomalies, phlebitis/thrombophlebitis, optic neuropathy, lower motor neuron lesions, tremors

Mild side effects

• Gastritis
• diarrhea
• abdominal pain
• dyspepsia
• nausea
• constipation
• musculoskeletal pain
• joint pain
• muscle pain
• flu-like illnesses

This medication should be stored in a sealed container to prevent exposure to air or moisture, ideally at room temperature between 1 and 30 degrees Celsius. Such storage helps to maintain the effectiveness of the medication.

Appearance

It is an injection in a colorless and transparent solution contained in a colorless and transparent glass prefilled syringe with a single-use injection needle attached.

Package unit

3ml x 1 vial